CN104353063A - 预防和控制人呼吸道合胞病毒感染的生物制剂及制备方法 - Google Patents
预防和控制人呼吸道合胞病毒感染的生物制剂及制备方法 Download PDFInfo
- Publication number
- CN104353063A CN104353063A CN201410561005.1A CN201410561005A CN104353063A CN 104353063 A CN104353063 A CN 104353063A CN 201410561005 A CN201410561005 A CN 201410561005A CN 104353063 A CN104353063 A CN 104353063A
- Authority
- CN
- China
- Prior art keywords
- anhydride
- preparation
- respiratory syncytial
- biological preparation
- syncytial virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 59
- 208000030925 respiratory syncytial virus infectious disease Diseases 0.000 title claims abstract description 10
- 150000008064 anhydrides Chemical class 0.000 claims abstract description 55
- 230000000694 effects Effects 0.000 claims abstract description 39
- 241000711920 Human orthopneumovirus Species 0.000 claims abstract description 16
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 claims description 39
- 239000000243 solution Substances 0.000 claims description 38
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 36
- 230000002265 prevention Effects 0.000 claims description 30
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 29
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 29
- CCTOEAMRIIXGDJ-UHFFFAOYSA-N 4-hydroxy-2-benzofuran-1,3-dione Chemical compound OC1=CC=CC2=C1C(=O)OC2=O CCTOEAMRIIXGDJ-UHFFFAOYSA-N 0.000 claims description 25
- 108090000623 proteins and genes Proteins 0.000 claims description 23
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 239000012460 protein solution Substances 0.000 claims description 18
- 239000011734 sodium Substances 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 13
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 12
- 229910019142 PO4 Inorganic materials 0.000 claims description 12
- 239000010452 phosphate Substances 0.000 claims description 12
- 229910052708 sodium Inorganic materials 0.000 claims description 12
- 108010010803 Gelatin Proteins 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 10
- 239000008273 gelatin Substances 0.000 claims description 10
- 229920000159 gelatin Polymers 0.000 claims description 10
- 235000019322 gelatine Nutrition 0.000 claims description 10
- 235000011852 gelatine desserts Nutrition 0.000 claims description 10
- 238000000746 purification Methods 0.000 claims description 10
- RINCXYDBBGOEEQ-UHFFFAOYSA-N succinic anhydride Chemical group O=C1CCC(=O)O1 RINCXYDBBGOEEQ-UHFFFAOYSA-N 0.000 claims description 10
- 241001597008 Nomeidae Species 0.000 claims description 9
- 238000004321 preservation Methods 0.000 claims description 9
- 239000004472 Lysine Substances 0.000 claims description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 8
- 239000012982 microporous membrane Substances 0.000 claims description 8
- 239000004475 Arginine Substances 0.000 claims description 7
- 241000287828 Gallus gallus Species 0.000 claims description 7
- 102000008192 Lactoglobulins Human genes 0.000 claims description 7
- 108010060630 Lactoglobulins Proteins 0.000 claims description 7
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 7
- 238000000926 separation method Methods 0.000 claims description 7
- 210000002966 serum Anatomy 0.000 claims description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 6
- 241000251468 Actinopterygii Species 0.000 claims description 5
- 102000004506 Blood Proteins Human genes 0.000 claims description 5
- 108010017384 Blood Proteins Proteins 0.000 claims description 5
- 102000001554 Hemoglobins Human genes 0.000 claims description 5
- 108010054147 Hemoglobins Proteins 0.000 claims description 5
- 238000000502 dialysis Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000000499 gel Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 241000725643 Respiratory syncytial virus Species 0.000 abstract description 42
- 241000700605 Viruses Species 0.000 abstract description 25
- 208000015181 infectious disease Diseases 0.000 abstract description 11
- 239000003814 drug Substances 0.000 abstract description 10
- 229940079593 drug Drugs 0.000 abstract description 6
- 150000001413 amino acids Chemical class 0.000 abstract description 5
- 230000000840 anti-viral effect Effects 0.000 abstract description 4
- 102000006395 Globulins Human genes 0.000 abstract 1
- 108010044091 Globulins Proteins 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000004048 modification Effects 0.000 description 25
- 238000012986 modification Methods 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 22
- 235000018102 proteins Nutrition 0.000 description 21
- 238000000034 method Methods 0.000 description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 108091005573 modified proteins Proteins 0.000 description 7
- 102000035118 modified proteins Human genes 0.000 description 7
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 6
- 241000725303 Human immunodeficiency virus Species 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 108010039918 Polylysine Proteins 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 229920000656 polylysine Polymers 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 108091006027 G proteins Proteins 0.000 description 4
- 108091000058 GTP-Binding Proteins 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 description 4
- 229940125777 fusion inhibitor Drugs 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 108010032976 Enfuvirtide Proteins 0.000 description 3
- 102000030782 GTP binding Human genes 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 229960002062 enfuvirtide Drugs 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 108050008461 Beta-lactoglobulin Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 208000005374 Poisoning Diseases 0.000 description 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 2
- 241000713311 Simian immunodeficiency virus Species 0.000 description 2
- 241000726445 Viroids Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 229940100050 virazole Drugs 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 241000711902 Pneumovirus Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- UQGFMSUEHSUPRD-UHFFFAOYSA-N disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane Chemical compound [Na+].[Na+].O1B([O-])OB2OB([O-])OB1O2 UQGFMSUEHSUPRD-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007499 fusion processing Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008004 immune attack Effects 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- -1 maleic anhydride anhydride Chemical class 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410561005.1A CN104353063B (zh) | 2014-10-21 | 2014-10-21 | 预防和控制人呼吸道合胞病毒感染的生物制剂及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410561005.1A CN104353063B (zh) | 2014-10-21 | 2014-10-21 | 预防和控制人呼吸道合胞病毒感染的生物制剂及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104353063A true CN104353063A (zh) | 2015-02-18 |
CN104353063B CN104353063B (zh) | 2017-10-24 |
Family
ID=52520436
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410561005.1A Active CN104353063B (zh) | 2014-10-21 | 2014-10-21 | 预防和控制人呼吸道合胞病毒感染的生物制剂及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104353063B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2716003C1 (ru) * | 2019-09-09 | 2020-03-05 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова" (ФГБНУ НИИВС им. И.И. Мечникова) | Применение сывороточного альбумина в качестве противомикробного агента |
CN111053892A (zh) * | 2019-12-24 | 2020-04-24 | 山西锦波生物医药股份有限公司 | 一种广谱抗肠道病毒的蛋白类药物及其应用 |
CN112316152A (zh) * | 2020-11-04 | 2021-02-05 | 山西锦波生物医药股份有限公司 | 经酸酐修饰的蛋白质抑制冠状病毒的方法 |
CN114805842A (zh) * | 2022-05-09 | 2022-07-29 | 浙江大学 | 一种天然大分子聚阴离子衍生物及绿色制备方法及应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102631666A (zh) * | 2012-03-14 | 2012-08-15 | 杨霞 | 一种预防和控制人乳头瘤病毒感染的生物制剂的制备方法 |
-
2014
- 2014-10-21 CN CN201410561005.1A patent/CN104353063B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102631666A (zh) * | 2012-03-14 | 2012-08-15 | 杨霞 | 一种预防和控制人乳头瘤病毒感染的生物制剂的制备方法 |
Non-Patent Citations (2)
Title |
---|
ZHIWU SUN ET AL.: "Intranasal Administration of Maleic Anhydride-Modified Human Serum Albumin for Pre-Exposure Prophylaxis of Respiratory Syncytial Virus Infection", 《VIRUSES》 * |
李琳 等: "酸酐修饰卵清蛋白HP-OVA与抗HIV药物协同作用预防HIV性传播的研究", 《第十届全国抗炎免疫药理学学术会议论文集》 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2716003C1 (ru) * | 2019-09-09 | 2020-03-05 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова" (ФГБНУ НИИВС им. И.И. Мечникова) | Применение сывороточного альбумина в качестве противомикробного агента |
CN111053892A (zh) * | 2019-12-24 | 2020-04-24 | 山西锦波生物医药股份有限公司 | 一种广谱抗肠道病毒的蛋白类药物及其应用 |
CN111053892B (zh) * | 2019-12-24 | 2023-11-17 | 山西锦波生物医药股份有限公司 | 一种广谱抗肠道病毒的蛋白类药物及其应用 |
CN112316152A (zh) * | 2020-11-04 | 2021-02-05 | 山西锦波生物医药股份有限公司 | 经酸酐修饰的蛋白质抑制冠状病毒的方法 |
CN114805842A (zh) * | 2022-05-09 | 2022-07-29 | 浙江大学 | 一种天然大分子聚阴离子衍生物及绿色制备方法及应用 |
CN114805842B (zh) * | 2022-05-09 | 2023-09-26 | 浙江大学 | 一种天然大分子聚阴离子衍生物及绿色制备方法及应用 |
Also Published As
Publication number | Publication date |
---|---|
CN104353063B (zh) | 2017-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Graham | Immunological goals for respiratory syncytial virus vaccine development | |
Crowe Jr | Respiratory syncytial virus vaccine development | |
ES2141065T3 (es) | Preparacion de vacuna de sub-unidades contra el virus respiratorio sincitial. | |
CN100354425C (zh) | 减毒的人-牛嵌合呼吸道合胞病毒疫苗的生产 | |
Melero et al. | The Pneumovirinae fusion (F) protein: A common target for vaccines and antivirals | |
HU229101B1 (en) | Dna transfection system for the generation of infectious influenza virus | |
CN108348593A (zh) | 基于人呼吸道合胞病毒(hrsv)病毒样颗粒(vlps)的疫苗 | |
Tang et al. | Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults | |
CN104353063A (zh) | 预防和控制人呼吸道合胞病毒感染的生物制剂及制备方法 | |
CN100491530C (zh) | 从克隆的核苷酸序列制备减毒嵌合呼吸道合胞病毒疫苗 | |
Devnath et al. | The pathogenesis of Nipah virus: A review | |
US20240082386A1 (en) | Methods for immunizing pre-immune subjects against respiratory syncytial virus (rsv) | |
CN102397559B (zh) | 广谱型流感疫苗及其制备方法 | |
CN105517568A (zh) | 防止病毒组分聚集的方法 | |
US20160228536A1 (en) | Recombinant respiratory syncytial virus (rsv) and vaccines | |
CN103757032B (zh) | 一种以流感病毒为载体的hcv嵌合疫苗及其制备方法 | |
CN101220095A (zh) | 抗呼吸道合胞病毒f蛋白和g蛋白的免疫球蛋白制备方法 | |
CN104402995A (zh) | 抗流感病毒鸡卵黄抗体的制备方法及应用 | |
CN101405027B (zh) | 基于病毒颗粒的鼻内流感疫苗 | |
CN106432439A (zh) | 一种牛呼吸道胞合体病毒抗原蛋白 | |
CN106749556A (zh) | 一种牛呼吸道胞合体病毒抗原蛋白 | |
Mayer et al. | The neutralizing capacity of antibodies elicited by parainfluenza virus infection of African Green Monkeys is dependent on complement | |
Paudel et al. | Role of trypsin in the replication of Avian metapneumovirus subtype C (strain MN-2a) and its entry into the Vero cells | |
CN106518988A (zh) | 一种牛呼吸道胞合体病毒抗原蛋白 | |
CN106540251A (zh) | 用于预防呼吸道合包体病毒感染的疫苗 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: FUDAN UNIVERSITY Effective date: 20150216 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20150216 Address after: 030032 Shanxi city of Taiyuan province by the economic and Technological Development Zone No. 18 North Street Applicant after: Taiyuan Jinbo Bio-Pharmaceutical Co.,Ltd. Address before: 030032 Shanxi city of Taiyuan province by the economic and Technological Development Zone No. 18 North Street Applicant before: Taiyuan Jinbo Bio-Pharmaceutical Co.,Ltd. Applicant before: Fudan University |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: 030032 Shanxi city of Taiyuan province by the economic and Technological Development Zone No. 18 North Street Applicant after: Shanxi Jin Bo Biomedics Inc. Address before: 030032 Shanxi city of Taiyuan province by the economic and Technological Development Zone No. 18 North Street Applicant before: Taiyuan Jinbo Bio-Pharmaceutical Co.,Ltd. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: TAIYUAN JINBO BIOMEDICAL TECHNOLOGY CO., LTD. TO: SHANXI JINBO BIOLOGICAL PHARMACEUTICAL CO., LTD. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP02 | Change in the address of a patent holder |
Address after: 030032 No.18, Jinbo street, Tanghuai Park, Taiyuan comprehensive reform demonstration zone, Taiyuan City, Shanxi Province Patentee after: SHANXI JINBO BIOMEDICAL Co.,Ltd. Address before: 030032 Shanxi city of Taiyuan province by the economic and Technological Development Zone No. 18 North Street Patentee before: SHANXI JINBO BIOMEDICAL Co.,Ltd. |
|
CP02 | Change in the address of a patent holder |